DLL3 and neoplasm: As radioimmunoconjugates targeting DLL3 can be readily converted into therapeutic agents using radionuclides including Lutetium-17710,11 or Actinium-225,10 our findings that tumor DLL3 expression and SSTR PET avidity may not be mutually exclusive invoke the intriguing possibility of either sequential or combinatorial targeting with DLL3 and SSTR radioligand therapies in PanNETs guided by functional imaging.